Stockreport

Novo Nordisk: Downgrading To 'Sell' As GLP-1 Pipeline Faces Many Risks [Seeking Alpha]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF CagriSema failed to achieve non-inferior weight loss versus Eli Lilly's tirzepatide in the pivotal REDEFINE-4 study, undermining NVO's obesity drug pipeline momentum. [Read more]